In vitro effects of Lidocaine on neutrophils from patients with sepsis
Research type
Research Study
Full title
In vitro effects of Lidocaine on neutrophils from patients with sepsis
IRAS ID
249025
Contact name
Thomas Craven
Contact email
Sponsor organisation
University of Edinburgh
Duration of Study in the UK
0 years, 4 months, 1 days
Research summary
We wish to obtain a single sample of blood (approximately 25 mls) from patients being treated on critical care for sepsis. Sepsis is life-threatening organ dysfunction caused by an individual's abnormal response to infection. It is a severe and common condition. The mainstay of treatments involve administering antibiotics to combat infection, and using life support techniques whilst the body and the antibiotics fight the infection. Few treatments are directed at the individual's abnormal response itself.
We want to take the blood sample to the laboratory and look at the effect of a drug called Lidocaine on a type of white blood cell called the neutrophil. Lidocaine has been used for many decades to provide local anaesthesia for a huge number of major and minor surgical procedures, but there is some evidence emerging that it exerts anti-inflammatory effects too. We want to look at the anti-inflammatory effects in the blood of patients with sepsis.
This drug will not be applied to the patient. All testing will be performed on the blood sample only and the sample will be disposed of following completion of the analysis.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
18/NW/0556
Date of REC Opinion
14 Sep 2018
REC opinion
Further Information Favourable Opinion